Unraveling lung cancer dynamics: a new metabolic signature improving the prediction of recurrence in resected lung adenocarcinoma - PubMed
a day ago
- #Metabolic Signature
- #Lung Adenocarcinoma
- #Prognostic Biomarker
- Study focuses on improving recurrence prediction in resected lung adenocarcinoma (LUAD) using a new metabolic signature.
- Identified a prognostic signature 'LMetSig' with 10 metabolic genes, stratifying patients into high- and low-risk groups for disease-free survival (DFS).
- TK1 gene within LMetSig shows promise as a LUAD-specific biomarker, correlating with shorter DFS when highly expressed.
- LMetSig enhances patient stratification alongside conventional parameters, aiding personalized treatment strategies.
- Research conducted with ethical approvals and no competing interests declared.